Back

Changes in lipid lowering therapy one year after percutaneous coronary intervention: data from the large contemporary ZON-HR registry

30 August 2024 (08:00 - 17:30)
Organised by: Logo
Congress Presentation Part of: Lipid-lowering therapies: new findings Lipids ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Ms Denise Peeters

Radboud University Medical Centre, Nijmegen (Netherlands (The))

8 More presentations in this session

Presentation thumbnail
Rationale and design of the SHASTA-3 and SHASTA-4 studies: randomized, double-blind, placebo-controlled, phase 3 studies of plozasiran in patients with severe hypertriglyceridemia
Doctor D. Gaudet (Montreal, CA)
Abstract Slides Video
Presentation thumbnail
Cardiovascular events in patients treated with bempedoic acid vs. placebo: systematic review and meta-analysis
Doctor D. Mutschlechner (Mistelbach, AT)
Abstract Slides Video
Presentation thumbnail
Association of lipid target achievement and cardiovascular outcomes following statin initiation: a population-based cohort study
Doctor J. Udell (Toronto, CA)
Abstract Slides Video
Presentation thumbnail
The impact of discontinuing proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors on clinical outcomes
Doctor H. Tsubata (Kyoto, JP)
Abstract Slides Video
Presentation thumbnail
Efficacy of lipid lowering therapy beyond statins to prevent cardiovascular events
Doctor I. Dykun (Essen, DE)
Abstract Slides Video

Access the full session

Session thumbnail
Lipid-lowering therapies: new findings

The Event

Event poster

ESC Congress 2024

30 August - 2 September 2024
You may be interested in
thumbnail
Congress Presentation
Suboptimal lipid lowering therapy after percutaneous coronary intervention and impact on 1 year outcomes: data from a large contemporary PCI registry
thumbnail
Congress Presentation
Association between high-intensity lipid-lowering therapy and atherosclerotic plaque content changes assed by iMAP-IVUS and near-infrared spectroscopy in patients with premature atherosclerosis
thumbnail
Congress Presentation
Prognostic significance of elevated lipoprotein(a) in long-term outcomes after PCI with drug-eluting stents

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources